Mylan markets Bumetanide.PITTSBURGH, Penn.--(BUSINESS WIRE)--Jan. 18, 1995--MYLAN LABORATORIES INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (NYSE NYSE See: New York Stock Exchange :MYL) announced today that it has begun marketing Bumetanide, the generic version of Roche's Bumex(R), one of the nation's leading pharmaceutical treatments for Edema associated with congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , hepatic and renal disease. The estimated market for this product in the United States is approximately $50 million. Milan Puskar, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented that the addition of Bumetanide to Mylan's product portfolio enhances the company's presence in the Cardiovascular market. Mylan currently markets 24 products for treatment of cardiovascular disease. CONTACT: Mylan Laboratories Inc. Patricia Sunseri, 412/232-0100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion